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[57] ABSTRACT 
B-methyl-B-butyrate (HMB) has been found to be mark» 
edly more effective for activating the immune function 
of T lymphocytes of mammals than a-ketoisocaproate 
(KIC). For activation of the T lymphocytes, B-methyl 
butyric acid or an edible water-soluble salt thereof is 
administered to the mammal by a route through which 
the HMB enters the blood of the mammal. The amount 
administered is suf?cient for effective enhancement of 
the blastogenesis of their T lymphocytes. The method is 
adapted for use with domestic mammals, including par» 
ticularly cattle, sheep, and swine. HMB can also be used 
with humans as an immune system stimulant. 
5 Claims, No Drawings 
4,992,470 
1 
METHOD OF ENHANCING I1\'IMUNE RESPONSE 
OF MAMMALS 
FIELD OF INVENTION 
The ?eld of the invention is methods of enhancing the 
immune response of mammals, and more particularly, 
the immune function of T lymphocytes. 
BACKGROUND OF INVENTION 
The keto analog of L-leucine (a dietarily essential 
amino acid) is a-keto-isocaproic acid, which is usually 
referred to as ketoisocaproate (KIC), or sometimes also 
as ketoleucine. In the accepted description of leucine 
metabolism, leucine is ?rst transaminated to its ketoa 
cid, a-ketoisocaproate (KIC). KIC then enters the mito 
chondria and is decarboxylated to isovalarylCoA by the 
branched chain ketoacid dehydrogenase. [See Krebs, et 
al., Adv. Enz. Reg. 15:375-394 (1976); and Paxton, et al., 
J. Biol. Chem: 257:14433-14439 (1982).] An alternate 
minor pathway has been described in the rat and human 
liver [Sabourn, et al., Fed. Prac. 38:283 (1979)]. This 
alternate oxidative pathway occurs in the cytosol and 
involves oxidation of KIC to B-hydroxy-B-methyl bu 
tyrate (HMB) by the enzyme KIC-oxygenase [Sabourn, 
et al., Arch. Biochem. 'Biophys. 206:132-144 (1981)]. 
The administration of keto analogs of amino acids has 
been proposed for treatment of certain disease condi 
tions in humans, such as uremia. [See, for example, 
Walser, et al., J. Clin. Inv., 52:678-690 (1973).] For 
nutritional purposes, it is known that KIC is an inef? 
cient substitute for leucine. Rat studies have shown that 
the feeding of KIC as a replacement for leucine requires 
the feeding of from two to three times as much KIC as 
the nutritionally required amount of leucine: Chawla, et 
al., J. Nutr., 105:798-803 (1975); and Boebel, et al., J. 
Nutr., 112: 1929-1939 (1982); and Chow, et al., J. Nutr., 
104: 1208-1214 (1974). 
It has been proposed to feed small amounts of KIC in 
conjunction with animal diets containing suf?cient leu 
cine for the purpose of improving the growth metabo 
lism of the animals. By using milligram amounts of KIC, 
some increases in the rates of weight gain and/or feed 
efficiencies have been obtained. [See, for example, US. 
Pat. Nos. 4,760,090 and 4,883,817.] With mature sheep 
being fed for W001 production, by feeding KIC the 
amount of wool produced may also be increased (US. 
Pat. No. 4,760,090). When lactating domestic animals, 
such as dairy cattle, are fed small amounts of KIC, the 
quantity of milk produced may be increased (U .8. Pat. 
No. 4,758,593). Egg production by laying chickens can 
also sometimes be increased (US. Pat. No. 4,760,531). 
Other effects of feeding KIC have been observed, in 
cluding cholesterol reduction in meat, milk and eggs 
(US. Pat. Nos. 4,760,090 and 4,760,531). U.S. Pat. No. 
4,835,185 describes the use of KIC as an im 
munomodulator for improving commercial perfor 
mance of domestic animals. Speci?cally, the feeding of 
KIC is disclosed as a means for activating the blastogen 
esis function of the immune systems of the domestic 
animals, the KIC being administered in an amount en 
hancing blastogenesis of their T lymphocytes. It also 
disclosed that the administration of KIC will usually 
decrease plasma cortisol levels. 
SUMMARY OF INVENTION 
,B-methyl-B-butyrate (HMB) has been found to be 












function of T lymphocytes of mammals than a~ 
ketoisocaproate (KIC). For activation of the T lympho 
cytes, B-methyl-butyric acid or an edible water-soluble 
salt thereof is administered to the mammal by a route 
through which the HMB enters the blood of the mam~ 
mal. The amount administered is suf?cient for effective 
enhancement of the blastogenesis of their T lympho 
cytes. The method is adapted for use with domestic 
mammals, including particularly cattle, sheep, and 
swine. HMB can also be used with humans as an im 
mune system stimulant. 
DETAILED DESCRIPTION 
The compound used for practicing the present inven 
tion is B-hydroxyrB-methyl butyric acid or an edible 
butyrate salt thereof. The free acid compound is also 
called B-hydroxy-isovalaryic acid. It has the following 
structure: 
CH3 OH 
This compound in both free acid and salt form is 
referred to herein generically as “HMB”. The acid form 
is designated HMB acid, and the speci?c salt form, such 
as the calcium or sodium salts, as Ca-HMB or Na-HMB. 
HMB has no isomers and accordingly does not exist in 
L or D forms. For the purpose of the present invention, 
it is preferred to employ HMB in the form of an edible 
salt rather than as the free acid. Preferably the salt form 
is water-soluble or becomes water-soluble in the stom 
ach or intestines. A preferred salt is the calcium salt 
(Ca-HMB). Sodium (Na-HMB) can also be used but 
Na-HMB is more hydroscopic than Ca-HMB. Other 
nontoxic salts can be used such as other alkali metal or 
alkaline earth metal salts. For mixing with feed ingredi 
ents, it is preferred that the salt form be dry, non-sticky, 
and ?nely-divided for blending with the feed materials. 
Ca-HMB is particularly desirable for these reasons. 
HMB is not known to be commercially available. 
However, procedures are known for synthesizing this 
compound from commercially available starting materi 
als.‘ For example, HMB can be synthesized by oxidation 
of diacetone alcohol (4-hydroxy-4-methyl-2-penta 
none). One suitable procedure is described by Coffman, 
et al., J. Am. Chem. Soc. 80:2882-2887, at 2885 (1958). 
As there described, B-hydroxy-isovalaryic acid (HMB) 
is synthesized by an alkaline sodium hypochlorite oxida 
tion of diacetone alcohol. The product is recovered in 
free acid form, which can be converted to the desired 
salt. For example, HMB can be prepared as its calcium 
salt (Ca-HMB) by a similar procedure to that of Coff 
man, et al. in which the HMB acid obtained is neutral 
ized with calcium hydroxide, and recovered by crystal 
lization from an aqueous ethanol solution. For example, 
a 95% ethanol solution can be used with the Ca-HMB at 
about a 10% concentration. Such a procedure is illus 
trated in more detail in the following examples. 
To assure administration at a desired level to domes 
tic animals, it is preferred to mix the dry HMB salt with. 
dry feed ingredients to a predetermined concentration. 
The HMB salt can be incorporated by dry blending 
using standard mixing equipment. The HMB should be 
substantially uniformly distributed throughout the feed. 
After mixing, if desired, the feed material may be fur 
4,992,470 
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ther processed, such as by conversion to pellets. Most 
feed compositions for domestic animals are composed 
of mixtures of feed ingredients. These feed compositions 
contain protein-providing ingredients as principal com 
ponents. These feed ingredients usually provide at least 
10% protein by weight on a total dry matter basis, and 
may contain as much as 24% or more by weight. Such 
mixed feed compositions may comprise complete feeds 
or feed concentrates. 
The method of this invention is believed to be suitable 
for use with all mammals, including particularly large 
domestic mammals such as cattle, sheep, swine, goats, 
and horses. It can also be used with mammals is adapted 
for use with zoo mammals. It is believed that a particu 
larly important use of the method is for improving the 
immune system of humans. 
When HMB is combined with the feed material as a 
uniform mixture, and the feed composition provides the 
major food source for the diet, the amount of HMB may 
be speci?ed in relation to the feed composition. For 
example, the admixed total ration feed compositions 
may contain from 0.001 to 0.5 wt % HMB (Ca-HMB 
and dry feed basis). On the same basis, a presently pre 
ferred range is from about 0.01 to 0.1 wt. % HMB. Such 
complete feed compositions will usually contain at least 
10% protein and may contain up to 24% protein (N x 
6.25). For example, bene?cial effects on the immune 
system, especially enhanced blastogenesis of T lympho 
cytes, can be obtained in preferred embodiments by 
incorporating from about 0.02 to 0.04 wt. % (dry basis) 
of Ca-HMB or molar equivalent amount of another 
edible nontoxic water-soluble salt of HMB. 
The foregoing feed composition levels of HMB relate 
primarily to feeds which are formulated to comprise 
substantially the total ration of the animal. Where feed 
supplements or feed concentrates are employed as the 
vehicle for administering the HMB, greater concentra 
tions may be required. The concentrations can be simi 
larly related to either the total diet of the animal, or to 
the body weight of the animals being fed. 
It is believed that some bene?cial effects on the im 
mune system can be obtained with as little as 0.05 to 0.2 
milligrams (mg) of HMB (Ca-HMB basis) per kilogram 
(kg) body weight per 24 hours. It will usually be desir 
able, however, to administer at least 0.5 mg/kg body 
weight/24 hrs (Ca-HMB basis). It will not usually be 
necessary to administer more than 100 mg HMB (Ca 
HMB basis) per kilogram of body weight per 24 hours, 
but higher amounts can be given up to 400 to 500 milli 
grams HMB on the stated basis. An optimum range for 
most domestic animals is believed to be from about 15 to 
35 mg/kg body weight/24 hrs (Ca-HMB basis). 
As previously indicated, it is preferred to combine 
HMB with a complete feed ration, feed concentrate, or 
other dry feed material being given to the cattle, sheep, 
swine, chickens, or turkeys. In certain cases, however, 
HMB could be administered by dissolving it in drinking 
water for the animals. However, control of the amount 
administered in water can be expected to be more dif? 
cult. For more precise control, HMB could be orally 
administered in the form of pellets. For example, such 
pellets could be spread as a top dressing on the daily (24 
hr) feed ration for each animal. ()ther methods of ad 
ministration could be used. 
As far as is known, HMB is not subject to signi?cant 
rumen destruction. Following oral administration, the 
HMB salt appears to pass intact through the rumen into 








the purpose of the present invention, it is believed that 
HMB should be absorbed into and distributed in the 
circulatory system. . 
The method of this invention can be used with cattle, 
including both beef cattle and dairy cattle, and with 
sheep, including both lambs and mature sheep, and 
swine, including both pigs and mature swine, and chick 
ens, including both chicks and mature egg laying chick 
ens, and also with turkeys being raised for meat produc 
tion, as well as other domestic animals such as horses, 
dogs, and cats. The method can be used to offset stress 
related conditions of domestic animals, such as cattle 
shipping fever, a bovine respiratory disease complex 
associated with the shipment of cattle. For ?ve to ten 
days prior to shipment, the cattle can be fed the HMB. 
Alternatively or additionally, oral administration of 
HMB for counteracting shipping fever, the HMB may 
be parenterally administered, such as by intramuscular 
injection. 
With respect to domestic animals subject to stress, it 
_is believed that a further bene?t of the HMB administra~ 
tion is to counteract increased cortisol. In most cases, it 
is believed that the improvement in T lymphocyte pro 
duction will be accompanied by a reduction in the 
blood cortisol level. 
USE OF HMB AS A HUMAN 
IMMUNOMODULATOR 
Puri?ed HMB, either in free acid or in the form of an 
edible salt, can be used as a human immunostimulator. 
Either oral or parenteral administration can be used. 
For example, HMB may be administered orally in the 
form of tablets or capsules, or it may be administered 
dissolved in an intravenous parenteral solution. For 
parenteral administration, the sodium salt of HMB (Na 
HMB) is preferred. 
Dose levels for a human subject can range from 200 
to 3,000 milligrams (mg) per 24 hours. This administra 
tion can be repeated on a daily basis until the desired 
effect on the immune system is obtained. A preferred 
administration range is from 500 to 2,500 mg/24 hrs. 
Based on the presently available experimental informa 
tion from animals models, it is believed that an optimum 
human dosage is from about 1 to 2 grams (grns) per day 
per 24 hrs. The dose level should be adequate so as to 
enhance the blastogenesis function of T lymphocytes. 
This is a function which can be monitored, and the dose 
required for the particular human subject can be regu 
lated to obtain and maintain enhanced blastogenesis. 
HMB salts, such as particularly the calcium salt, can 
be tabletted in uniform dose amounts. If needed a tablet 
ting composition such as dextrose or sucrose can be 
admixed with the HMB salt for forming into tablets. 
Alternatively, dose amounts of the HMB salt may be 
incorporated in capsules. For example, each tablet or 
capsule may be prepared to contain one gram or two 
grams of HMB on a Ca-HMB basis. 
The method of this invention is further illustrated by 
the following experimental examples. 
EXAMPLE 1 
Preparation of Ca-HMB 
Reaction is contained in a 5000 ml round bottom ?ask 
?tted with condenser. Constant mixing is achieved by a 
magnetic stirrer. 
Add in sequence: 
1 gallon bleach (5.25% Sodium Hypochlorite) 
4,992,470 
45g NaOH powder 
Mix well. 
150 ml 1,4 Dioxane 
93ml 4—Hydroxy-4-Methyl—2-Pentanone. 
Re?ux for 40 minutes. 
Transfer solution to washtub and cool for 30 minutes 
under a hood. 
Adjust pH to 5 using concentrated H2504. (HMB is 
stabilized.) 
Transfer solution to cooling pans under a vent hood, 
so that air is drawn in over the solution for faster 
evaporation. Use the steam table if possible. 
Let solution evaporate overnight. Sodium sulfate 
salts will precipitate out forming a slurry. 
Transfer slurry to washtub, and adjust pH to 1 using 
concentrated H2804. 
Salts and solution may be extracted separately de-v 
pending on the volume available after evaporation. 
Transfer solution with/without salts to 10 liter bottle, 
and wash 4x with approximately 2 liters of Ethyl 
Acetate (Acetate layer contains HMB.) 
Save ethyl acetate layer. Discard ?nal acid layer. 
Roto Vap Acetate layer at 50° C. 
Salts may precipitate out. 
Solubilize Ultra-pure H2O. 
Add an equal volume of Ethyl Acetate and re 
extract. Save ethyl acetate layer. 
Roto Vap Acetate layer at 50° C. 
Increase Temperature to 70° C. and continue Roto 
Vap. Remaining solution contains HMB and is 
ready for crystallization. 
The dried HMB acid is neutralized with calcium 
hydroxide powder. The powder is added to the stirring 
HMB acid until a basic pH is reached. The pH is as 
sessed with pH paper. The HMB solidi?es at this point 
and is subsequently dissolved in hot 95% ethanol at a 
volume of ~ 10 times the original acid volume. Material 
that does no dissolve is removed from the liquid by 
centrifugation or ?ltration. The ethanol-HMB solution 
is then placed at —20%F until the mixture crystallizes. 
Usually this takes overnight but ca take 2-3 days. The 
HMB crystals are then ?ltered under vacuum through 
paper towels and liquid squeezed out of the cake-like 
crystals. The HMB crystals are then redissolved in hot 
ethanol and the process repeated. In most cases 3 re 
crystallizations are suf?cient to fully remove any yel 
low color from the crystals. Further puri?cation can be 
achieved by further crystallization. After the ?nal crys 
tallization the HMB is placed in a pan and freeze-dried 
overnight to obtain an anhydrous calcium HMB pow 
der ready for feed additive use. 
EXAMPLE 2 
Stability of HMB in the Rumen 
Rumen ?uid was collected from a ?stulated steer. 
After ?ltration and dilution (1:4) with an arti?cial sa 
liva, 25ml of the solution was added to 50ml plastic 
tubes. Each tube was ?tted with a one-way valve to 
allow gases to escape while not allowing air into the 
tube. Each tube was then gassed with C02 and incu 
bated at 39° C. After 30 min a solution of KIC or HMB 
was added to the tube in concentrations to simulate 
what would be present in the rumen of an animal con 
suming .05% of the diet as KIC or HMB. It was esti 
mated that a 50uM concentration would be attained in 











?uid were taken and analyzed for KIC and HMB. The 
results are shown in Table A. 
TABLE A 
Time after 
Addition (min) KIC HMB 
0 30' 60 
l5 15 76 
60 2 71 
240 2 74 
480 l 74 
‘initial concentration of KIC was estimated. The initial concentrations should have 
been ~50 uM but because of the rapid degradation of KIC in the rumen, KlC was 
already being degraded before the 0 time collection could be cooled and processed. 
The foregoing shows that KIC is rapidly destroyed 
by the rumen bacteria while HMB is quite stable in a 
rumen environment. 
EXAMPLE 3 
In Vitro Effects of HMB on Cultured LYmphocytes 
Materials and Methods 
Lymphocyte Blastogenesis Determinations. Blood 
collections, lymphocyte isolation and blastogenesis as 
says were performed on isolated bovine cells by using a 
3-d culture procedure as described previously in Kuhl 
man, et a1. (1988), J. Nutr., 118:1564-1569. 
Isolated lymphocytes were exposed to l and 10 mM 
Leu and KIC and the metabolites isovalarate, B 
hydroxy-B-methyl butyrate (HMB), B-hydroxy-B 
methyl glutarate, butyrate, acetate, acetone, acetoace 
tate, and B-hydroxy butyrate (BOHB). The cells were 
then stimulated with the mitogen phytohemagglutinin, 
and incorporation of 3I-I-thymidine into the DNA of the 
dividing lymphocytes was measured. 
Leucine and Leucine Metabolites. Most of the com 
pounds listed in Table B were purchased from Sigma 
Chemical Company, St. Louis, MO. KIC was pur 
chased from SOBAC (Paris, France), HMB was synthe 
sized as described in Example 1, and the calcium salt of 
HMB was puri?ed by crystallization in 95% ethanol. 
The calcium salt was converted to a sodium salt form 
and used in subsequent assays. The pH of all compounds 
was adjusted to approximately 7.3. Compounds were 
passed through a 0.2-um ?lter assembly to assure steril 
ity. 
The results of this study are summarized in Table B. 
TABLE B 
Effect of Leucine or Leucine Metabolites on In Vitro 
Lymphocyte Blastogenesis Compared with No Additions 
(Mean Percent Chan_ge~SEM) 
Metabolite Final % Change from 
Added Concentration No Additive P< 
Leucine 1 mM —12 i 6 0.10 
a-ketoisocaproate 1 mM —3 i- 7 
B-hydroxy-B-methyl 1 mM +28 : 9 0.10 
glutarate 
B-hydroxybutyrate 1 mM +25 i 6 0.05 
B-hydroxy-B- methyl l mM +78 :L 13 0.01 
butyrate 
The data of Table B shows that leucine (Leu) tended 
to suppress blastogenesis while a-ketoisocaproate 
(KIC) had no effects on blastogenesis. B-hydroxy-B 
methyl glutarate and B-hydroxybutyrate increased blas 
togenesis slightly while B-hydroxy-B-methyl butyrate 
(HMB) was 3 times more potent than any other com 
4,992,470 
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pound at 1 mM concentrations. This study indicates that 
KIC and Len have no effect on he immune system 
directly, but that only by partial conversion to HMB 
they positively effected lymphocyte function. 
EXAMPLE 4 
HMB Effects on Lymphocyte Function in Lambs 
Materials and Methods 
Animals and Experimental Design. Three sets of twin 
lambs were housed individually in ?berglass pens. Ani 
mals were randomly assigned to control or HMB diets, 
using a standard basal diet with and without 0.05% 
HMB. 
Blood Sampling and Lymphocyte Preparation. In the 
?rst experiment, animals were bled for lymphocyte 
blastogenesis assays and T-cell subset analysis 38, 45, 
and 52 days after dietary treatments began. Blood (50 
ml) was collected, aseptically, via jugular venepuncture 
into 10 ml acid-citrate-dextrose anticoagulant (44 g 
trisodium citrate, 16 g citric acid and 50 g dextrose per 
1 of triple-distilled water). Blood was centrifuged, the 
buffy coat removed, and 1 volume of buffy coat was 
diluted with 0.5 volume of plasma which was added to 
2 volumes of Sepracell-MN (Sepratech Corporation, 
Oklahoma City, Okla.). After further centrifugation at 
1500 x g for 25 min, the mononuclear layer was re 
moved and washed twice with Hanks’ balanced salt 
solution (HBSS; Gibco, Grand Island, N.Y.) by centri 
fuging at 150 x g for 15 min. The remaining white blood 
cells were resuspended in HBSS, and the total number 
of white blood cells was determined by using an auto 
mated cell counter (Coulter Electronics, Hialeah, Fla.). 
The concentration of the cells was adjusted to 1x206" 
cells/ml with HBSS. 
Lymphocyte Blastogenesis Determinations. Blasto 
genesis assays were performed on isolated lymphocytes 
by using a 3-d culture procedure as described previ 
ously. Brie?y, isolated lymphocytes were cultured in 
microtiter plates with 2 X 105” cells in 0.15 ml of culture 
medium/well. Culture medium consisted of RPMI 
media-1640 (Gibco, Grand Island, N.Y.) containing 
15% heat-inactivated fetal bovine serum and 1% antibi 
otic-antimycotic solution (Gibco, Grand Island, N.Y.). 
Unstimulated and mitogen-stimulated cultures were 
assayed in triplicate. Mitogens used were phytohemag 
glutinin-P (PHA), concanavalin A (ConA) and poke 
weed mitogen (PWM). PHA was purchased from Difco 
Laboratories, Detroit, MI; ConA from Miles Laborato 
ries, Elkhart, IN; and PWM from Gibco, New York, 
N.Y. Microtiter plates were incubated at 37' C. in a 
humidi?ed 5% CO2 atmosphere. After 48 h, 0.25 uCi of 
3I-I-thyrnidine (New England Nuclear, Boston, Mass.) 
was added to each well. Eighteen hours later, the cul 
tures were harvested onto glass-?ber ?lters with an 
automated sample harvester (Flow Laboratories, Rock 
ville, Mo.), ?lters were placed in 10 ml CytoScint scin 
tillation solution (ICN Biomedicals, Irvine, CA), and 
radioactivity was counted in a liquid scintillation 
counter. This procedure is similar to that described by 
Kuhlman, et al., J. Nutr., 118:1564-1569. 
The results of the study of lymphocyte immune func 








Decays Per Min of 3H Thymidine 
Incorporated into Isolated Lymphocytes 
PHA ConA PWM 
Stimulation Stimulation Stimulation 
Before 
Treatment 
Control 37,000 48,000 32,000 
HMB 23,000 41,000 21,000 
After 
Treatment 
Control 15.000 19,000 18,000 
HMB 18,000 21,000 25,000 
Change in - 22,000 —29,000 — 14,000 
control 
Change in HMB —5,000 -20,000 +4,000 
The data of Table C indicates that HMB tended to 
effect the decline in lymphocyte function that occurred 
in these sheep. Why lymphocyte function in these ani 
mals decreased with time is not known. It may have 
been due to age, stress, or other unknown events. There 
is no reason to associate the decline with the HMB 
administration since it occurred to a greater extent in 
the control animals. 
EXAMPLE 5 
Stimulation of Pig Immune Function 
Materials and Methods 
Twelve speci?c pathogen free (SPF) pigs 4-5 weeks 
of age were distributed into two groups, each being 
blocked by gender and litter. All pigs were fed approxi 
mately 4% of their body weight of a commercially 
purchased starter ration. Pigs were penned individually 
and allowed free access to water. 
Diets were supplemented with one of two dietary 
treatments: Control (limestone)(n=6) and HMB (n= 6). 
Dietary treatments were fed at 0.05% of the body 
weight. HMB was synthesized by the method of Exam 
ple 1. One week later, pigs were injected with 5 ml/ 30 
kg body weight of a 20% suspension of sheep red blood 
cells (SRBC) subcutaneously. 
Fourteen days post dietary treatments, all pigs were 
challenged via intratracheal inoculation with 5 ml of a 
ground lung suspension. The suspension was derived 




mentally inoculated with Mycoplasma hyopneumoniae. 
Blood samples were collected once a week for the eval 
uation of antibodies produced in response to the SRBC 
and Mycoplasma hyopneumoniae antigenic stimuli. An 
agglutination assay was used to determine antibody 
titers produced against SRBC. Titers to Mycoplasma 
hyopneumoniae were determined using a serum comple 
ment ?xation assay. At necropsy, the extent of macro 
scopic pneumonia lesions was recorded and samples 
from all pigs were submitted for histopathology to assay 
microscopic lesions. Lung and bronchi samples were 
cultured and evaluated for the presence of Mycoplasma 
species (i.e., .M. hyorhinis, .M. hyosynoviae, and M hyop 
neumoniae) and other easily isolated bacteria (i.e., bor 
detella, pasteurella, and hemophilus). 
The iliac lymph nodes, liver, spleen, and gastrocne 
mius muscle were removed from the carcass and 
weighed. The nasal cavity was examined for evidence 
of Bordetella broncheseptica infection that will result in 
nasal turbinate degeneration. Nasal degeneration was 
scored as to severity with 0 indicating no lesions and the 
4,992,470 
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highest score, 3, corresponding to moderate degenera 
tion. 
The results ar summarized below in Table D. 
TABLE D 
Effect of HMB Supplementation on 
Disease Parameters in Figs Infected with Myconlasma 
Control HMB 
% lung showing lesions 18.7 13.7 
Bronchi, presence of bacteria 1.1 0.8 
Lung ?uorescent antibodies to 12.6 10.3 
M. hyapneumaniae 
M. hyopneumoniae peak liters 7.1 6.7 
Red blood cell titers (dilution) 11.6 15.5‘ 
day 10-15 
Nasal degeneration scores 1.6 0.8’ 
(0 = no lesion) 
Spleen (g) 101 94 
Iliac lymph node (g) 3.8 3.3‘ 
The results presented in Table D describe the macro 
scopic and microscopic lung evaluations and also the 
antibody values derived from M. hyopneumaniae stim 
uli. Although the ?uorescent antibody technique 
showed the presence of M. hyopneumoniae colonies 
were decreased, when HMB was fed no signi?cant 
differences were seen in the lung or bronchi evalua 
tions. There were also no signi?cant differences seen 
between dietary treatments when M. hyopneumoniae 




cally signi?cant, HMB fed animals had a lesser extent of 30 
mycoplasmal lung infection than did KIC-fed or con 
_ trol animals. HMB-fed animals demonstrated a signi? 
cant decrease in nasal degeneration due to bordetella 
infection. The spleen and the iliac lymph node were 
smaller in HMB-fed animals. 
In the comparison of control and HMB fed pigs in 
fected with M. hyopneumoniae, the results suggested 
that HMB can prevent some of the lung damage associ 







agent is very dif?cult to treat with antibiotics because of 
the location within the bronchi of the lung. Therefore. 
stimulation of the animals’ lymphocytes to enter and 
suppress 0 kill the Mycoplasmal organism is desirable. 
Evidence for this effect was the lower incidence of 
diseased lung and fewer numbers of Mycoplasma in the 
lung tissue. Also lower antibodies to the Mycoplasma in 
the plasma suggest less antigenic stimulation. Other 
opportunistic bacteria also appeared to be suppressed 
by HMB treatment as evidenced by fewer bacteria cul 
tured in the bronchi and less severe lesions of the nasal 
turbinates caused by the bacteria Bordetella bron» 
cheseptica. 
I claim: 
1. The method of activating the immune function of T 
lymphocytes of mammals in need of such treatment, 
comprising administering to said mammals ,B-hydroxy= 
B-methyl butyric acid or an edible water-soluble salt 
thereof (HMB), said HMB being administered by a 
route in which the HMB enters the blood of the mam= 
mals and in an amount effective for enhancing the blas= 
togenesis of their T lymphocytes. 
2. The method of claim 1 in which said mammals are 
selected from the group of domestic animals consisting 
of cattle, sheep, and swine. 
3. The method of claim 1 in which said mammals are 
humans. 
4. The method of claim 2 in which the HMB is admin“ 
istered by admixing with feed for said mammals, and the 
HMB (Ca-HMB basis) is administered in an amount 
from 0.5 to 100 milligrams (mgs) per kilogram (kg) of 
body weight per 24 hours. _ 
5. The method of claim 3 in which said HMB (Ca 
HMB basis) is orally or parenterally administered in an 
amount of 500 to 2,500 milligrams (mg) per human 
subject per 24 hours. 
i it it it i 
